G551D

Based on promising results from a late-stage trial, Vertex Pharmaceuticals is hoping to expand the indication of its cystic fibrosis drug Kalydeco (ivacaftor) in other genetically defined patient populations.

European Commission Approves Vertex's Personalized CF Drug Kalydeco

FDA Grants Standard Review for Pfizer's NDA for Bosutinib in Ph-Positive CML

After data from a Phase III trial yielded significant improvements in the lung function of study participants who received the investigational drug VX-770, Vertex said it would work with regulatory agencies in the US and abroad to speed the drug's approval.

The New York Times profiles 23andMe's Anne Wojcicki and describes how she bounced back from a bad year.

Fotis Kafatos, the founding president of the European Research Council, has died, according to the Associated Press.

In PLOS this week: genomic analysis of honeybee disease, microRNA profiles of people with lupus nephritis, and more.

The Verge's Angela Chen tried out a gene test for fitness advice, but didn't learn much new information.